Effects of Anti-GPIbα antibody on the expression of platelet GPIbα, CD62P and CD63 in maintenance hemodialysis patients
-
Graphical Abstract
-
Abstract
Objective To explore the effects of anti-platelet membrane glycoprotein Ib alpha (GPIbα) antibody on the expression of peripheral GPIbα, alpha particle membrane glycoprotein (CD62P) and lysosomal membrane protein (CD63) in maintenance hemodialysis (MHD) patients. Methods Thirty-seven patients with chronic renal failure undergoing MHD from March 2016 to March 2018 in the Department of Nephrology in Eighth Affiliated Hospital of Sun Yat-sen University and 31 healthy people in the Physical Examination Center were enrolled in this study. Using flow cytomery, the expression of platelet member GPIbα, CD62P and CD63 was detected before and after addition of anti-GPIbα antibody in MHD patients. Results The expression of platelet membrane GPIbα in no antibody treatment group (29.9±4.9)% was significantly lower than in control group (63.8±9.0)% and antibody treatment group (42.3±6.5)% (both P<0.01). The expression of CD62P and CD63 in no antibody treatment group (50.9±7.5)% and (54.1±5.5)% was significantly higher than that in the control group(23.3±8.7% and 30.9±6.2%) and antibody treatment group (36.5±2.0)% and (47.2±2.2)% (P<0.01, P<0.05). Conclusions Anti-GPIbα antibody can regulate platelet function and activity by up-regulating the expression of platelet membrane GPIbα, and down-regulating the expression of CD62P and CD63 in MHD patients, as a result to suppress adhesion and aggregation of platelets and thrombosis, and reduce the possibility of thromboembolism events in MHD patients.
-
-